-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
- Cosmetic Ingredient
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Such stem cells are the basis of a new branch of therapy that uses these unspecialized cells to restore tissue
damaged by disease.
Image credit: UC San Diego School of Health Sciences
Stem cells show particular promise
in treating diseases for which there are few other effective treatments.
In these therapies, stem cells are introduced into the body, where they develop into specialized cells that repair, restore, replace, or regenerate cells
damaged by disease.
As part of a statewide effort to advance stem cell therapy, the California Institute for Regenerative Medicine (CIRM) awarded $8 million
to the UC San Diego Alpha Stem Cell Clinic.
The funding will be used to support the clinic's mission to provide new stem cell-based therapies
to patients with difficult diseases.
Alpha Clinic — named after being the first of its kind — is a network of clinics across California that aims to bridge the gap
between stem cell research and clinical applications.
The system brings together clinical, research, regulatory, and administrative teams to accelerate clinical trials and streamline the patient experience
.
"We're trying to change the way we do medicine," said Catriona Jamieson, MD, director of the UC San Diego Alpha Stem Cell Clinic and director
of the Division of Regenerative Medicine at the UC San Diego School of Medicine.
Alpha Clinic helps academic and industry experts work together to bring world-class technology directly to patients
.
”
The grant is part of CIRM's most recent series of grants totaling $72 million to expand the Alpha clinic network
.
When the program launched in 2015, UC San Diego was one of
three founding institutions.
The new funding will expand the project to nine locations
in the state.
In the 7 years since its inception, UC San Diego Alpha Stem Cell Clinic has conducted 59 clinical trials treating 277 patients
with neurodegeneration, diabetes and various cancers with new therapies.
The trials test cellular, gene and immunotherapies developed through growing partnerships between UC San Diego and local biotech and pharmaceutical companies
.
Recent milestones include the completion of a Phase I trial using neural stem cells to treat spinal cord injuries in which patients showed improved motor function after treatment, and a Phase III registration trial
approved by the U.
S.
Food and Drug Administration (FDA) for a blood cancer stem cell-targeted monoclonal antibody.
The latest funding will help expand clinical trials at La Jolla and Hillcrest Medical Centers and create a clinical fellowship program to educate more physicians
in advanced regenerative medicine therapies.
Another major goal of the clinic is to increase accessibility and awareness
of stem cell science.
A portion of the funding will go toward new patient education programs and efforts to make treatment
more accessible to historically underserved communities in San Diego and Empire County.
"Patients come to us when anything else doesn't work, so we're excited to be able to provide our community with new therapies
that aren't available anywhere else in this country," Jamison said.
"Alpha Clinic's highly collaborative infrastructure will help us develop and validate high-quality stem cell therapies at an unprecedented rate, the effects of which will be seen
in California and beyond.
"
# # #